Trials / Completed
CompletedNCT02549417
Phase 3 Study of KHK7580
Phase 3 Study of KHK7580 (A Clinical Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Peritoneal Dialysis)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate efficacy and safety of KHK7580 orally administered once daily for 32 weeks for patients with secondary hyperparathyroidism receiving peritoneal dialysis. After 32-week treatment period, the subjects will receive KHK7580 in the 20-week extension period to evaluate long-term safety and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KHK7580 | Oral administration |
Timeline
- Start date
- 2015-09-29
- Primary completion
- 2016-12-22
- Completion
- 2016-12-22
- First posted
- 2015-09-15
- Last updated
- 2017-07-05
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02549417. Inclusion in this directory is not an endorsement.